Patents by Inventor Birgitte Koch Michelsen

Birgitte Koch Michelsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9603904
    Abstract: The present invention relates to an insulin derivative for the treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of the insulin derivative, wherein said insulin derivative exhibits a prolonged profile of action and wherein said dosages are administered at intervals longer than 24 hours.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: March 28, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Thue Johansen, Birgitte Koch Michelsen, Berit Edsberg
  • Publication number: 20140220029
    Abstract: Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound.
    Type: Application
    Filed: April 10, 2014
    Publication date: August 7, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Birgitte Koch Michelsen, Jeppe Sturis
  • Publication number: 20110230402
    Abstract: The present invention relates to an insulin derivative for the treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of the insulin derivative, wherein said insulin derivative exhibits a prolonged profile of action and wherein said dosages are administered at intervals longer than 24 hours.
    Type: Application
    Filed: October 29, 2009
    Publication date: September 22, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Thue Johansen, Birgitte Koch Michelsen, Berit Edsberg
  • Publication number: 20080213288
    Abstract: Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound.
    Type: Application
    Filed: May 2, 2008
    Publication date: September 4, 2008
    Applicant: Novo Nordisk A/S
    Inventors: Birgitte Koch Michelsen, Jeppe Sturis
  • Publication number: 20040037826
    Abstract: Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound.
    Type: Application
    Filed: June 16, 2003
    Publication date: February 26, 2004
    Inventors: Birgitte Koch Michelsen, Jeppe Sturis
  • Publication number: 20030235583
    Abstract: Methods and uses for the prevention and intervention of Type 1 diabetes and LADA comprising administration of a modulator of CD3 and a beta cell resting compound.
    Type: Application
    Filed: June 11, 2003
    Publication date: December 25, 2003
    Inventors: Jeppe Sturis, Birgitte Koch Michelsen
  • Patent number: 6040134
    Abstract: The present invention relates to a method of diagnosing preclinical insulin-dependent diabetes mellitus by determining the T cell response to a specific islet cell antigen fetal antigen 1 (FA1) or the presence of autoantibodies against FA1 in serum, a test kit for use in the method, as well as a pharmaceutical composition of FA1 and a method for use of the pharmaceutical composition for therapy of insulin-dependent diabetes mellitus.
    Type: Grant
    Filed: July 15, 1997
    Date of Patent: March 21, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Ole Dragsbaek Madsen, Birgitte Koch Michelsen, Jacob Steen Petersen, Bart O. Roep, Borge Teisner